

PRESS RELEASE

Piramal Enterprises Ltd. to Cover Cost for COVID-19 Vaccination for All its Employees and Family Members

- **Offers reimbursement of cost to ~27000 employees and their families in India**
- **Sets-up virtual vaccine Helpdesks across its India offices to assist employees**

Mumbai, India | March 15, 2021: Piramal Enterprises Limited ('PEL', NSE: PEL, BSE: 500302, 912460) today announced that it will absorb the cost of COVID-19 vaccination for all its employees and their immediate family members that are eligible and choose to receive the vaccination in India. The company has also set up virtual vaccine helpdesks across its offices in India to address employee queries on the vaccination including enabling registrations, information on vaccination centres, etc. Opting for the vaccine is at the discretion of employees and they are urged to make an informed decision for themselves and their family.

“Driven by our values, we believe that employees are our greatest assets, and we remain committed to ensuring their wellbeing and welfare. We are happy to absorb the cost of the COVID-19 vaccination, as well as to support them through the process, should they choose to get vaccinated.” said **Nandini Piramal, Executive Director, Piramal Enterprises Limited.**

Piramal Group's core values of Knowledge, Action, Care and Impact have been an integral part of the Company's guiding philosophy of 'Doing Well and Doing Good'. In line with this philosophy, the Company has undertaken this initiative to help about ~27000 employees and their families get vaccinated free of cost, encouraging more people towards a safer future.

About Piramal Enterprises Ltd:

Piramal Enterprises Limited (PEL), a publicly listed company in India, has diversified business interests in Financial Services and Pharmaceuticals. PEL's consolidated revenues were ~US\$1.7 billion in FY2020, with ~34% of revenues generated from outside India.

In Financial Services, the Company offers a wide range of financial products and solutions, with exposure across both wholesale and retail financing. The wholesale lending business provides financing to real estate developers, as well as corporate clients in non-real estate sectors. Within retail lending, the Company offers housing loans to individual customers and is building a multi-product retail lending platform. India Resurgence Fund (IndiaRF), the distressed asset investing platform in partnership with Bain Capital Credit, invests in equity and/or debt across non-real estate sectors. The Company has long-standing partnerships with leading institutional investors that include - CPPIB, APG, Bain Capital Credit, CDPQ, and Ivanhoé Cambridge. PEL also has equity investments in the Shriram Group, a leading financial conglomerate in India.

Piramal Pharma Limited (PPL), a subsidiary of PEL, offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 14 global facilities and a global distribution network in over 100 countries. PPL includes an integrated contract development and manufacturing (CDMO) business, Complex hospital generics business, and India Consumer Products business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, PPL received 20% strategic growth investment from the Carlyle Group.

For more information visit: www.piramal.com, [Facebook](#), [Twitter](#), [LinkedIn](#)

For Media Queries:

Dimple Kapur/Niyati Vora | Corporate Communications
Dimple.Kapur@piramal.com / Niyati.Vora@piramal.com